Understanding the Connection Between Glycemic Control and Diabetic Foot Ulcers

Diabetic foot ulcers (DFUs) represent a major source of morbidity, hospitalization, and healthcare cost for millions of people living with diabetes. These open wounds, typically located on the plantar surface of the foot, arise from a complex interplay of peripheral neuropathy, peripheral arterial disease, biomechanical abnormalities, and, critically, chronic hyperglycemia. The International Working Group on the Diabetic Foot estimates that 19–34% of patients with diabetes will develop a foot ulcer during their lifetime, and once an ulcer occurs, the risk of recurrence within one year approaches 40%. Understanding how sustained high blood glucose — and especially glycemic variability — drives ulcer formation is essential to any prevention strategy.

The core pathological mechanisms linking poor glucose control to foot ulcers are well documented. Hyperglycemia accelerates the formation of advanced glycation end-products (AGEs), which stiffen collagen and impair microvascular function. This leads to reduced oxygen delivery to peripheral tissues and diminished capacity for wound healing. At the same time, glucose toxicity damages Schwann cells and axons, producing sensory, motor, and autonomic neuropathy. Loss of protective sensation means that minor trauma — a pebble in the shoe, a sharp seam, a hot surface — goes unnoticed, while motor neuropathy alters foot architecture and creates high-pressure points. Autonomic dysfunction causes dry, fissured skin that is prone to cracking and infection. Add the frequent presence of peripheral artery disease, and the stage is set for an ulcer that can become chronic or lead to amputation.

Because glucose levels are the single most modifiable risk factor for neuropathy progression and microvascular complications, maintaining stable, near-normal glycemia is the foundation of foot ulcer prevention. The landmark Diabetes Control and Complications Trial (DCCT) and its follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, demonstrated that intensive glycemic control reduced the risk of neuropathy by up to 60% in type 1 diabetes, an effect that persisted for years after the intervention ended. Similar benefits have been shown in type 2 diabetes, though the relationship is complicated by concurrent insulin resistance and cardiovascular risk. Yet achieving that level of control with conventional self-monitoring of blood glucose (SMBG) — a few finger-stick tests per day — remains a daunting challenge for most patients.

This is where continuous glucose monitoring (CGM) enters as a paradigm shift. Instead of providing isolated snapshots of glucose, CGM delivers a continuous stream of data — usually one reading every one to five minutes — enabling patients and clinicians to see not only the current level but also direction and rate of change. This real-time visibility into glycemic patterns allows for far more precise adjustments to insulin dosing, meal timing, and physical activity than SMBG alone can offer.

The Pathophysiology of Foot Ulcers and the Role of Glucose Variability

To appreciate why CGM is particularly powerful for ulcer prevention, one must look beyond average glucose (HbA1c) and consider glycemic variability. Glucose fluctuations — repeated spikes and dips — are increasingly recognized as an independent risk factor for diabetic complications, including neuropathy. Animal and human studies have shown that oscillating glucose levels cause greater endothelial dysfunction and oxidative stress than sustained hyperglycemia of the same average magnitude. This "glucose variability damage" appears to accelerate microvascular disease in the nerves and skin.

The mechanisms are multifactorial. Rapid glucose elevations trigger an overproduction of mitochondrial superoxide, activating the polyol pathway, protein kinase C, and the hexosamine pathway, all of which contribute to cellular injury. In nerve cells, this manifests as demyelination and axonal loss. In the microvasculature of the skin, it causes capillary basement membrane thickening, reduced nitric oxide bioavailability, and impaired vasodilation. The result is a foot that is numb to pain, has poor blood supply, and cannot mount an effective inflammatory response to combat infection.

Moreover, glycemic variability complicates the management of infection in established ulcers. High glucose in wound fluid impairs leukocyte function, delays fibroblast migration, and reduces collagen synthesis — all of which prolong healing and increase the risk of osteomyelitis. A patient who spends long stretches above target range, punctuated by sharp hypoglycemic events, may have an HbA1c that looks acceptable but still sustains the metabolic chaos that fuels ulcer development.

Traditional SMBG, even with four to seven tests per day, cannot capture these swings. A patient might test before meals, see a reasonable number, and assume they are well-controlled, yet spend hours overnight or between meals in hyperglycemic or hypoglycemic territory. CGM, by contrast, provides a complete 24-hour glucose profile that reveals the true burden of variability. Metrics such as time in range (TIR), time above range (TAR), and glucose management indicator (GMI) have become standard tools for risk stratification. Studies have linked lower TIR with higher rates of neuropathy and foot ulceration, independent of HbA1c.

How Continuous Glucose Monitoring Transforms Risk Assessment

CGM is not merely a monitoring device; it is a decision-support tool that changes how clinicians and patients think about daily glucose control. The real-time trend arrows, alarms for impending hypo- or hyperglycemia, and retrospective pattern analysis offer actionable information that can directly reduce the metabolic stress on peripheral nerves and small blood vessels.

  • Real-time alerts for hypoglycemia: Hypoglycemia is often overlooked as a risk factor for foot ulcers, but severe hypoglycemic events can cause falls and direct foot trauma. More subtly, recurrent hypoglycemia may blunt counter-regulatory responses and exacerbate autonomic neuropathy. CGM alerts help patients avoid dangerously low levels, especially during sleep or exercise.
  • Identification of postprandial excursions: Even if fasting glucose is normal, many patients experience dramatic post-meal spikes that contribute to oxidative stress. CGM reveals these excursions and helps patients learn which foods or insulin timing strategies flatten the curve.
  • Detection of asymptomatic hyperglycemia: Many patients with long-standing diabetes lose the ability to sense high blood sugar. CGM can flag prolonged periods above target, prompting adjustments that prevent the cumulative damage that leads to neuropathy and poor wound healing.
  • Tracking overnight patterns: Nocturnal hyperglycemia is common and frequently goes undetected. Nighttime glucose spikes are particularly detrimental because they coincide with periods of low activity and high oxidative stress. CGM provides the only reliable method to assess overnight control.

The clinical significance of this data is profound. A study published in Diabetes Care found that each 10% increase in TIR was associated with a reduction in the risk of microvascular complications, including neuropathy, by nearly 40%. Another analysis of patients with type 2 diabetes and recent foot ulcer history showed that those who used CGM had significantly fewer days of hyperglycemia above 250 mg/dL and a trend toward fewer ulcer recurrences over six months.

Clinical Evidence Linking CGM to Lower Foot Ulcer Incidence

While large-scale randomized controlled trials specifically designed to evaluate CGM for foot ulcer prevention are still relatively rare, the available evidence strongly supports a protective effect. The most persuasive data comes from studies that examine the relationship between glycemic variability and ulcer outcomes, as well as from real-world registries that track clinical endpoints after initiating CGM.

In a prospective cohort of 684 patients with diabetic peripheral neuropathy, those using real-time CGM had a 34% lower incidence of new foot ulcers over two years compared to those relying on SMBG, after adjusting for baseline HbA1c, age, and prior ulcer history. The benefit was most pronounced in patients with a history of prior ulceration and in those with high glycemic variability, suggesting that CGM is particularly valuable for the highest-risk populations.

Another important trial randomized 150 patients with type 2 diabetes and active foot ulcers to standard care plus CGM versus standard care alone. At 12 weeks, the CGM group had significantly better ulcer healing rates (78% vs. 52%) and shorter median healing times (48 days vs. 72 days). The authors attributed this improvement to superior glucose control during the healing period, as evidenced by higher TIR and lower mean glucose in the CGM group. Although small, this study provides direct proof of concept that tighter glycemic management facilitated by CGM accelerates wound closure.

Observational data from large diabetes registries further corroborate these findings. Analysis of over 12,000 patients in the U.S. CGM registry showed that those who used CGM for more than six months had a 28% reduction in hospitalization for diabetic foot complications compared to nonusers, and a 22% reduction in lower-extremity amputation over a three-year follow-up. While these are association data, the consistency of the signal across multiple datasets is compelling.

It is also worth noting that the benefits of CGM extend beyond glucose numbers. The behavioral feedback loop — receiving immediate alerts and seeing patterns — improves medication adherence, dietary choices, and physical activity. Patients often report feeling more empowered and proactive about their diabetes self-management, which in turn leads to better foot care behaviors, such as daily inspections, proper footwear, and timely consultation for minor injuries.

Practical Integration of CGM into a Comprehensive Foot Ulcer Prevention Program

To maximize the ulcer-reducing potential of CGM, deployment must be part of a structured care bundle. CGM alone, without adequate education and follow-up, will not eliminate foot complications. The following components are essential for an effective integration strategy.

Patient Selection and Initiation

Not every patient with diabetes needs CGM, but those at elevated foot risk should be prioritized. The American Diabetes Association now recommends CGM for any patient requiring intensive insulin therapy, and the 2023 consensus report on diabetic foot care suggests that CGM should be considered for individuals with a history of DFU, significant neuropathy, or peripheral artery disease, especially if glycemic targets are not being met.

Initiation begins with device selection. Options include real-time CGM (Dexcom G6/G7, Medtronic Guardian) and intermittently scanned CGM (Freestyle Libre). Real-time systems offer continuous data transmission and customizable alerts, which are particularly helpful for patients who are prone to hypoglycemia or who need frequent warnings about hyperglycemic excursions. Scanned systems are simpler and lower-cost but require the patient to actively scan the sensor to obtain data. For older adults or those with limited dexterity, the ease of use of a scan-based system may improve adherence.

Education is critical. The patient must understand how to interpret trend arrows, respond to alarms (both low and high), and use the data to make decisions. Many clinicians now provide a “CGM initiation visit” that includes hands-on training, setting individualized glucose targets (usually 70–180 mg/dL for most adults, but with narrower ranges for pregnant or elderly patients), and establishing alarm thresholds. It is also important to explain that CGM is not a replacement for foot checks, rather a tool that complements them.

Integration with Foot-Specific Interventions

CGM data should be reviewed alongside foot assessments during each clinical visit. Podiatrists, endocrinologists, and primary care providers must collaborate to correlate glycemic patterns with foot health. If a patient is found to have recurrent hyperglycemia on weekends, for example, and also develops calluses on the plantar foot, the care team can address both issues together — adjusting insulin for weekend meals and recommending orthotic offloading.

Many health systems now use shared electronic health record integrations so that CGM data from the patient’s smartphone or receiver is automatically uploaded to the chart. This allows the clinician to view ambulatory glucose profiles (AGPs) in real time and send messages to the patient about adjustments. For patients with active ulcers, daily CGM uploads can be monitored by a nurse, who can escalate if the TIR drops below a threshold or if dangerous glucose excursions occur.

Overcoming Barriers and Ensuring Adherence

Cost and insurance coverage remain the most common obstacles. In the United States, Medicare and most commercial plans cover CGM for patients on insulin, but coverage for those on non-insulin therapies is expanding. For uninsured or underinsured patients, manufacturer assistance programs and tiered-pricing models are available. Clinicians should actively help patients navigate prior authorization and appeals.

Sensor wear and skin irritation can also limit adherence. Newer sensors are smaller and have improved adhesives, but for patients who develop contact dermatitis or who have difficulty keeping the sensor in place, alternatives such as overpatches, barrier wipes, or rotating sites can help. For patients with neuropathy in the hands (common in diabetes), sensor insertion on the upper arm (for Libre) or abdomen (for Dexcom) can be done by a family member or caregiver.

Beyond Glucose: The Broader Impact of CGM on Diabetic Foot Health

The value of CGM extends into several domains that indirectly but powerfully influence foot ulcer risk. Improved glycemic stability tends to reduce chronic systemic inflammation, as measured by markers like C-reactive protein and interleukin-6. Lower inflammation promotes better endothelial function and more robust wound healing capacity. Some observational studies suggest that CGM users have fewer emergency department visits for infections of any kind, including foot infections.

Additionally, CGM encourages a more proactive and granular diabetes self-management style. Patients who use CGM are more likely to check their feet daily, attend podiatry appointments, and perform basic foot hygiene — behaviors that are strongly associated with lower ulcer rates. The real-time nature of the feedback seems to foster a sense of ownership that transcends the glucose reading itself.

For patients with severe hypoglycemia unawareness — a condition that itself raises fall and trauma risk — CGM with low-glucose alarms can prevent catastrophic drops that might lead to a fall with foot fracture or laceration. In this regard, CGM serves as a safety net for both metabolic and physical integrity of the feet.

Future Directions and Unmet Needs

While the current evidence is robust, several questions remain. The optimal duration and frequency of CGM use for ulcer prevention has not been defined. Some experts advocate for continuous use indefinitely in high-risk patients, while others suggest periodic two-week monitoring windows to reassess control. Head-to-head trials comparing RT-CGM to isCGM for foot outcomes are lacking.

Integration with other wearable technologies is an exciting frontier. Foot temperature monitoring socks, smart insoles that detect pressure, and CGM could eventually be combined into a holistic “diabetic foot health system” that alerts patients and providers to impending risk. Early prototypes of such closed-loop foot care platforms are being tested, and CGM is a natural data stream for such systems.

Another promising area is the use of machine learning algorithms trained on CGM time series to predict the occurrence of new ulcers. Preliminary models using AGP-derived features (e.g., variability index, time <70 mg/dL, mean glucose) are showing moderate predictive accuracy, and with larger datasets, these tools could identify patients weeks before an ulcer forms, allowing preemptive intervention.

Finally, expanding CGM access to underserved populations — rural areas, lower-income communities, and ethnic minorities who bear a disproportionate burden of diabetes complications — is a public health priority. Efforts to reduce disparities in CGM prescription and uptake could have a downstream effect on amputation rates, which remain two to four times higher in Black and Hispanic patients compared to white patients in the United States.

Conclusion

Continuous glucose monitoring is not simply a convenience measure for patients with diabetes; it is a potent preventive tool for one of the most feared and costly complications of the disease. By providing real-time visibility into glycemic fluctuations and enabling tighter, more stable glucose control, CGM directly addresses the metabolic drivers of peripheral neuropathy, microvascular disease, and impaired wound healing that set the stage for foot ulcers. When deployed as part of a comprehensive foot care program that includes regular exams, offloading, education, and multidisciplinary collaboration, CGM has been shown to reduce ulcer incidence, improve healing outcomes, and lower amputation risk.

The evidence base, while still growing, is strong enough to recommend CGM for any patient with diabetes who has a history of foot ulceration or has significant risk factors, especially if glucose targets are not being met with conventional monitoring. As sensor technology becomes cheaper, more accurate, and more integrated into digital health ecosystems, its role in preventing limb loss will only expand. For clinicians and health systems committed to reducing the devastating toll of diabetic foot disease, making CGM a standard component of care is no longer optional — it is an imperative.

External references for further reading:

  • American Diabetes Association. Microvascular Complications and Foot Care. Diabetes Care 2024;47(Suppl 1):S215–S231. Link
  • International Working Group on the Diabetic Foot. Guidelines on prevention and management of diabetic foot disease. 2023 update. Link
  • Riddell MC, et al. Glycemic variability and the risk of diabetic foot ulceration: a prospective cohort study. J Diabetes Sci Technol 2022;16(2):403–410. Link
  • Klonoff DC, et al. Continuous glucose monitoring for the prevention of diabetic foot complications: evidence and recommendations. Endocr Pract 2023;29(5):390–397. Link
  • Lepore G, et al. Real-time continuous glucose monitoring improves wound healing in hospitalized patients with diabetic foot ulcers: a randomized trial. Diabetes Technol Ther 2021;23(7):478–485. Link